Canada markets open in 6 hours 1 minute
  • S&P/TSX

    20,491.01
    +284.60 (+1.41%)
     
  • S&P 500

    4,088.85
    +80.84 (+2.02%)
     
  • DOW

    32,654.59
    +431.17 (+1.34%)
     
  • CAD/USD

    0.7797
    -0.0012 (-0.15%)
     
  • CRUDE OIL

    113.62
    +1.22 (+1.09%)
     
  • BTC-CAD

    38,207.91
    -944.38 (-2.41%)
     
  • CMC Crypto 200

    669.17
    +426.49 (+175.74%)
     
  • GOLD FUTURES

    1,810.50
    -8.40 (-0.46%)
     
  • RUSSELL 2000

    1,840.30
    +56.87 (+3.19%)
     
  • 10-Yr Bond

    2.9680
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,487.75
    -72.50 (-0.58%)
     
  • VOLATILITY

    26.10
    -1.37 (-4.99%)
     
  • FTSE

    7,507.49
    -10.86 (-0.14%)
     
  • NIKKEI 225

    26,911.20
    +251.45 (+0.94%)
     
  • CAD/EUR

    0.7412
    +0.0015 (+0.20%)
     

Novamind to Participate in Citi's Psychedelic Drug Video Call Series

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, ON / ACCESSWIRE / January 20, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that it will participate in Citi's Psychedelic Drug Video Call Series to be held virtually on January 25, 2022.

Neena Bitritto-Garg, Vice President Research Analyst, Biotech, at Citi, will host Novamind's Chief Executive Officer, Yaron Conforti and Chief Medical Officer, Reid Robison, MD, MBA, for a fireside chat at 10:00 AM ET.

"Novamind has an established track record as a leader in commercializing psychedelic medicine and other innovative mental health therapies through a growing network of clinics and hosting an exciting pipeline of clinical trials for major drug developers," said Mr. Conforti. "I look forward to introducing Citi's clients to Novamind and expanding our relationships with a global base of institutional investors."

To register for the call, please contact your Citi representative directly.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Investor Relations
Email: IR@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.



View source version on accesswire.com:
https://www.accesswire.com/684714/Novamind-to-Participate-in-Citis-Psychedelic-Drug-Video-Call-Series

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting